Related Experiment Video
Updated: May 31, 2026
08:45
New Thrombectomy Technique for Total Portal Vein Thrombosis in Liver Transplantation
Published on: June 27, 2025
Vascular targeting of antithrombotic agents
Ronald Carnemolla1, Vladimir R Muzykantov
1Department of Pharmacology, University of Pennsylvania, Philadelphia, USA.
IUBMB Life
|July 19, 2011
Summary
Current antithrombotic drugs show limited effectiveness. This review explores targeted delivery methods for enhanced antithrombotic therapies to combat thrombosis.
Area of Science:
- Pharmacology
- Biomedical Engineering
- Hematology
Background:
- Pharmacological agents for thrombosis prophylaxis and treatment exhibit limited efficacy.
- Existing therapies face challenges in achieving optimal therapeutic outcomes.
- There is a need for improved strategies to manage thrombotic disorders.
Purpose of the Study:
- To review the limited efficacy of current pharmacological agents for thrombosis.
- To highlight advancements in targeted delivery of antithrombotic agents.
- To explore novel strategies for enhancing antithrombotic therapy.
Main Methods:
- Literature review of current pharmacological agents for thrombosis.
- Analysis of targeted delivery systems for antithrombotic agents.
- Discussion of drug delivery to specific targets including fibrin, platelets, red blood cells, and endothelium.
Main Results:
- Current antithrombotic agents demonstrate restricted efficacy in managing thrombosis.
- Targeted delivery systems show promise for improving antithrombotic drug action.
- Delivery to fibrin, platelets, red blood cells, and endothelium represents key strategies.
Conclusions:
- Enhanced efficacy in thrombosis treatment necessitates novel therapeutic approaches.
- Targeted drug delivery systems offer a promising avenue for improving antithrombotic therapies.
- Further research into targeted delivery mechanisms is crucial for advancing thrombosis management.
Related Concept Videos
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:30Venous Thrombosis I: Introduction
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
01:30Venous Thrombosis IV: Nursing Management
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...